Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.625
-0.055 (-3.27%)
Apr 29, 2026, 3:42 PM EDT - Market open
Cardiff Oncology Revenue
In the year 2025, Cardiff Oncology had annual revenue of $593.00K, down -13.18%. Cardiff Oncology had revenue of $243.00K in the quarter ending December 31, 2025, with 60.93% growth.
Revenue (ttm)
$593.00K
Revenue Growth
-13.18%
P/S Ratio
187.34
Revenue / Employee
$19,129
Employees
31
Market Cap
111.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 593.00K | -90.00K | -13.18% |
| Dec 31, 2024 | 683.00K | 195.00K | 39.96% |
| Dec 31, 2023 | 488.00K | 102.00K | 26.42% |
| Dec 31, 2022 | 386.00K | 27.00K | 7.52% |
| Dec 31, 2021 | 359.00K | -7.00K | -1.91% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Verrica Pharmaceuticals | 35.58M |
| Seer, Inc. | 16.58M |
| Cibus | 3.64M |
| NeOnc Technologies Holdings | 39.99K |
| InflaRx | 34.44K |
| Genelux | 8.00K |
CRDF News
- 23 hours ago - Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 days ago - Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity - GlobeNewsWire
- 8 days ago - Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 - GlobeNewsWire
- 11 days ago - Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting - GlobeNewsWire
- 19 days ago - Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth - GlobeNewsWire
- 4 weeks ago - Cardiff Oncology Transcript: KOL event - Transcripts
- 5 weeks ago - Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer - GlobeNewsWire
- 5 weeks ago - Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting - GlobeNewsWire